Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADUS NASDAQ:CSTL NASDAQ:GRAL NASDAQ:PGNY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADUSAddus HomeCare$119.22+3.1%$100.24$87.95▼$124.43$2.16B0.88238,298 shs196,083 shsCSTLCastle Biosciences$23.89-2.3%$22.39$14.59▼$44.28$741.26M1283,664 shs366,214 shsGRALGRAIL$64.42-3.5%$66.73$29.95▼$118.84$2.87B3.22447,505 shs789,463 shsPGNYProgyny$30.76-2.6%$28.18$16.10▼$33.06$2.47B1.011.07 million shs1.74 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADUSAddus HomeCare+3.09%+5.22%+23.12%+22.96%+9.27%CSTLCastle Biosciences-2.25%-2.53%-1.69%-1.44%+46.30%GRALGRAIL-3.52%-11.40%-2.28%+29.64%+68.33%PGNYProgyny-2.63%-4.59%+7.89%+66.99%+32.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADUSAddus HomeCare$119.22+3.1%$100.24$87.95▼$124.43$2.16B0.88238,298 shs196,083 shsCSTLCastle Biosciences$23.89-2.3%$22.39$14.59▼$44.28$741.26M1283,664 shs366,214 shsGRALGRAIL$64.42-3.5%$66.73$29.95▼$118.84$2.87B3.22447,505 shs789,463 shsPGNYProgyny$30.76-2.6%$28.18$16.10▼$33.06$2.47B1.011.07 million shs1.74 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADUSAddus HomeCare+3.09%+5.22%+23.12%+22.96%+9.27%CSTLCastle Biosciences-2.25%-2.53%-1.69%-1.44%+46.30%GRALGRAIL-3.52%-11.40%-2.28%+29.64%+68.33%PGNYProgyny-2.63%-4.59%+7.89%+66.99%+32.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADUSAddus HomeCare 2.73Moderate Buy$131.5010.30% UpsideCSTLCastle Biosciences 2.80Moderate Buy$42.4377.60% UpsideGRALGRAIL 2.30Hold$67.785.21% UpsidePGNYProgyny 2.85Moderate Buy$33.258.09% UpsideCurrent Analyst Ratings BreakdownLatest CSTL, GRAL, PGNY, and ADUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2026PGNYProgyny BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$27.00 ➝ $34.007/28/2026PGNYProgyny BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/24/2026ADUSAddus HomeCare CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform7/24/2026PGNYProgyny BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $40.007/22/2026PGNYProgyny Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$38.007/21/2026PGNYProgyny Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $36.007/17/2026GRALGRAIL Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026GRALGRAIL TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/15/2026GRALGRAIL MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$58.00 ➝ $65.007/13/2026PGNYProgyny KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $35.007/9/2026ADUSAddus HomeCare Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADUSAddus HomeCare$1.42B1.56$6.69 per share17.81$58.72 per share2.03CSTLCastle Biosciences$344.23M2.10$1.09 per share21.95$16.13 per share1.48GRALGRAIL$147.17M18.79N/AN/A$66.13 per share0.97PGNYProgyny$1.29B1.87$0.72 per share42.91$5.99 per share5.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADUSAddus HomeCare$95.91M$5.4122.0417.561.596.89%9.80%7.34%8/3/2026 (Estimated)CSTLCastle Biosciences-$24.16M-$0.44N/AN/AN/A-3.78%-2.77%-2.30%7/30/2026 (Estimated)GRALGRAIL-$408.35M-$10.37N/AN/AN/A-253.22%-16.42%-14.34%8/11/2026 (Estimated)PGNYProgyny$58.52M$0.7739.9522.452.515.23%13.34%9.03%8/6/2026 (Estimated)Latest CSTL, GRAL, PGNY, and ADUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026GRALGRAIL-$2.6556N/AN/AN/A$42.39 millionN/A8/6/2026Q2 2026PGNYProgyny$0.3350N/AN/AN/A$348.63 millionN/A8/3/2026Q2 2026ADUSAddus HomeCare$1.69N/AN/AN/A$376.24 millionN/A7/30/2026Q2 2026CSTLCastle Biosciences-$0.44N/AN/AN/A$86.24 millionN/A5/7/2026Q1 2026PGNYProgyny$0.2560$0.50+$0.2440$0.29$326.47 million$328.50 million5/6/2026Q1 2026CSTLCastle Biosciences-$0.49-$0.49N/A-$0.49$79.23 million$84.23 million5/5/2026Q1 2026GRALGRAIL-$2.7629-$2.29+$0.4729-$2.29$39.16 million$40.79 million5/4/2026Q1 2026ADUSAddus HomeCare$1.52$1.62+$0.10$1.36$366.41 million$363.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADUSAddus HomeCareN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/AGRALGRAILN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADUSAddus HomeCare0.081.831.83CSTLCastle Biosciences0.026.756.53GRALGRAILN/A11.7411.74PGNYProgynyN/A2.132.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADUSAddus HomeCare95.35%CSTLCastle Biosciences92.60%GRALGRAILN/APGNYProgyny94.93%Insider OwnershipCompanyInsider OwnershipADUSAddus HomeCare4.10%CSTLCastle Biosciences6.10%GRALGRAIL1.83%PGNYProgyny9.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADUSAddus HomeCare50,65918.67 million17.90 millionOptionableCSTLCastle Biosciences54030.33 million28.48 millionOptionableGRALGRAIL1,36042.92 million42.13 millionOptionablePGNYProgyny31078.33 million70.58 millionOptionableCSTL, GRAL, PGNY, and ADUS HeadlinesRecent News About These CompaniesProgyny (NASDAQ:PGNY) Downgraded to Hold Rating by Barclays15 minutes ago | marketbeat.comFifth Third Bancorp Increases Stock Position in Progyny, Inc. $PGNYJuly 27 at 3:27 AM | marketbeat.comPrincipal Financial Group Inc. Purchases 78,198 Shares of Progyny, Inc. $PGNYJuly 26 at 4:40 AM | marketbeat.comBTIG Research Raises Progyny (NASDAQ:PGNY) Price Target to $40.00July 26 at 1:54 AM | americanbankingnews.comProgyny (NASDAQ:PGNY) Stock Rating Lowered by Wall Street ZenJuly 25, 2026 | americanbankingnews.comProgyny (NASDAQ:PGNY) Cut to "Buy" at Wall Street ZenJuly 25, 2026 | marketbeat.comProgyny (NASDAQ:PGNY) Price Target Raised to $40.00 at BTIG ResearchJuly 24, 2026 | marketbeat.com76,500 Shares in Progyny, Inc. $PGNY Bought by SEB Asset Management ABJuly 24, 2026 | marketbeat.comProgyny, Inc. Announces Details for Its Second Quarter 2026 Results ReportJuly 23, 2026 | globenewswire.comCanaccord Genuity Group Forecasts Strong Price Appreciation for Progyny (NASDAQ:PGNY) StockJuly 21, 2026 | marketbeat.comProgyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for InvestorsJuly 19, 2026 | fool.com5 Top Stocks With Relative Price Strength to Buy Right NowJuly 17, 2026 | zacks.com40,000 Shares in Progyny, Inc. $PGNY Acquired by Calamos Advisors LLCJuly 17, 2026 | marketbeat.comProgyny (PGNY) Stock May Be 50% Undervalued On Fresh Analyst UpgradesJuly 15, 2026 | finance.yahoo.comDoes Rising Analyst Optimism On June Trends Reframe Progyny’s (PGNY) Employer-Demand Story?July 15, 2026 | finance.yahoo.comProgyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue?July 14, 2026 | zacks.comHsbc Holdings PLC Sells 61,703 Shares of Progyny, Inc. $PGNYJuly 14, 2026 | marketbeat.comProgyny (NASDAQ:PGNY) Sets New 52-Week High - Still a Buy?July 13, 2026 | marketbeat.comKornitzer Capital Management Inc. KS Reduces Position in Progyny, Inc. $PGNYJuly 12, 2026 | marketbeat.comProgyny (NASDAQ:PGNY) Upgraded at Zacks ResearchJuly 10, 2026 | marketbeat.comWhy Progyny (PGNY) Might be Well Poised for a SurgeJuly 9, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSTL, GRAL, PGNY, and ADUS Company DescriptionsAddus HomeCare NASDAQ:ADUS$119.22 +3.57 (+3.09%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$119.22 0.00 (0.00%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.Castle Biosciences NASDAQ:CSTL$23.89 -0.55 (-2.25%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$23.79 -0.10 (-0.42%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.GRAIL NASDAQ:GRAL$64.42 -2.35 (-3.52%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$66.02 +1.60 (+2.48%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.Progyny NASDAQ:PGNY$30.76 -0.83 (-2.63%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$30.76 +0.00 (+0.02%) As of 07/28/2026 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
